OR WAIT null SECS
Risankizumab is the latest biologic approved by the FDA and the first-ever IL-23A targeted therapy approved for the treatment of patients with Crohn's disease.
Every year there are seemingly more and more biologics approved by the US Food and Drug Administration (FDA) for patients with inflammatory bowel disease.
However, with the number of therapies on the market, it can get confusing looking at which biologic targets which pathway and whether they are earmarked for patients with Crohn’s disease, patients with ulcerative colitis, or patients with either disease.
The following list will focus on some of the more common therapies for IBD, what they are used for, and what they target specifically.